Agenus Inc. (AGEN)
Stock Price Chart
Key Info
| Market Cap | 680.73M |
| Revenue (ttm) | 91.41M |
| Net Income (ttm) | -173.57M |
| Shares Out | 190.15M |
| EPS (ttm) | -1.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | November 23 |
| Last Price | $3.58 |
| Previous Close | $3.65 |
| Change ($) | -0.07 |
| Change (%) | -1.92% |
| Day's Open | 3.70 |
| Day's Range | 3.56 - 3.73 |
| Day's Volume | 1,898,553 |
| 52-Week Range | 1.82 - 5.63 |
More Stats
| Market Cap | 680.73M |
| Enterprise Value | 603.34M |
| Earnings Date (est) | Mar 18, 2021 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 190.15M |
| Float | 157.45M |
| EPS (basic) | -1.09 |
| EPS (diluted) | -1.09 |
| FCF / Share | -0.76 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 23.73M |
| Short Ratio | 14.85 |
| Short % of Float | 15.07% |
| Beta | 2.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 7.45 |
| PB Ratio | n/a |
| Revenue | 91.41M |
| Operating Income | -105.53M |
| Net Income | -173.57M |
| Free Cash Flow | -138.97M |
| Net Cash | 77.39M |
| Net Cash / Share | 0.41 |
| Gross Margin | -20.01% |
| Operating Margin | -115.45% |
| Profit Margin | -189.90% |
| FCF Margin | -152.04% |
| ROA | -34.78% |
| ROE | n/a |
| ROIC | 270.60% |
Analyst Forecasts
Analyst Consensus: n/a
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 150 | 36.78 | 42.88 | 22.57 | 24.82 | 6.98 | 3.05 | 15.96 | 2.76 | 3.36 |
| Revenue Growth | 307.92% | -14.21% | 89.95% | -9.04% | 255.67% | 129.13% | -80.92% | 479.17% | -17.97% | - |
| Gross Profit | 150 | 36.78 | 42.88 | 22.57 | 24.82 | 6.98 | 2.51 | 15.29 | 2.76 | 3.24 |
| Operating Income | -64.33 | -125 | -107 | -106 | -74.00 | -36.62 | -24.98 | -6.74 | -19.09 | -21.75 |
| Net Income | -108 | -160 | -121 | -127 | -87.88 | -42.49 | -30.07 | -11.32 | -23.28 | -21.91 |
| Shares Outstanding | 135 | 111 | 98.42 | 87.07 | 78.21 | 59.75 | 29.77 | 23.63 | 19.90 | 16.11 |
| Earnings Per Share | -0.80 | -1.44 | -1.23 | -1.46 | -1.13 | -0.71 | -1.12 | -0.51 | -1.21 | -1.41 |
| Operating Cash Flow | -18.68 | -131 | -94.23 | -79.96 | -47.18 | -38.23 | -19.53 | 1.01 | -16.25 | -14.76 |
| Capital Expenditures | -4.66 | -3.59 | -3.00 | -12.52 | -3.59 | -2.82 | -0.81 | -0.10 | -0.03 | -0.08 |
| Free Cash Flow | -23.34 | -135 | -97.23 | -92.48 | -50.77 | -41.05 | -20.35 | 0.91 | -16.28 | -14.84 |
| Cash & Equivalents | 61.81 | 53.05 | 60.19 | 76.44 | 172 | 40.22 | 27.35 | 21.47 | 10.75 | 19.78 |
| Total Debt | 23.39 | 13.36 | 163 | 131 | 114 | 6.03 | 8.87 | 35.92 | 32.92 | 34.20 |
| Net Cash / Debt | 38.42 | 39.70 | -103 | -54.25 | 57.20 | 34.20 | 18.49 | -14.45 | -22.18 | -14.41 |
| Assets | 155 | 136 | 138 | 157 | 242 | 74.53 | 34.84 | 29.09 | 19.81 | 30.91 |
| Liabilities | 387 | 311 | 214 | 196 | 172 | 51.51 | 39.32 | 46.69 | 40.64 | 45.61 |
| Book Value | -225 | -172 | -75.82 | -39.13 | 70.73 | 23.02 | -4.48 | -23.18 | -26.41 | -14.71 |
Company Profile
Company Details
| Full Name | Agenus Inc. |
| Country | United States |
| Employees | 328 |
| CEO | Garo H. Armen |
Stock Information
| Ticker Symbol | AGEN |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: AGEN |
| IPO Date | February 4, 2000 |
Description
Agenus, a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.